These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 32472530)

  • 41. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
    Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
    Wagner HJ; Wessel M; Jabs W; Smets F; Fischer L; Offner G; Bucsky P
    Transplantation; 2001 Sep; 72(6):1012-9. PubMed ID: 11579293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
    Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
    Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.
    Marjańska A; Pogorzała M; Dziedzic M; Czyżewski K; Richert-Przygońska M; Dębski R; Bogiel T; Styczyński J
    Front Immunol; 2024; 15():1427637. PubMed ID: 39055711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
    Choi JH; Park BB; Suh C; Won JH; Lee WS; Shin HJ
    J Korean Med Sci; 2010 Apr; 25(4):523-6. PubMed ID: 20357991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differentiating Between Epstein-Barr Virus-positive Lymphoid Neoplasm Relapse and Post-transplant Lymphoproliferative Disorder After Sex-mismatched Hematopoietic Stem Cell Transplantation.
    Kurashige R; Kurashige M; Okada Y; Higuchi K; Yuda S; Hino A; Miyamura T; Ichii M; Fukushima K; Honma K; Takeuchi M; Yokota T; Ishikawa J; Sawada A; Shibayama H; Hosen N; Morii E
    Am J Surg Pathol; 2024 Apr; 48(4):395-405. PubMed ID: 38287877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EBV load in whole blood correlates with LMP2 gene expression after pediatric heart transplantation or allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Reiter A; Wagner HJ
    Transplantation; 2014 May; 97(9):958-64. PubMed ID: 24389909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
    Marjanska A; Styczynski J
    Expert Opin Biol Ther; 2023; 23(6):539-552. PubMed ID: 36971380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report.
    Carden MA; Caltharp S; Yee ME; Haight AE; Westblade LF; Park S
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):e310-e314. PubMed ID: 27403771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
    Balaguer-Rosello A; Piñana JL; Bataller L; Montoro J; Romero S; Navarro I; Lorenzo I; Andreu R; Guerreiro M; Aguilar C; Gorriz D; Dominguez L; de la Puerta R; Gómez I; Solves P; Jarque I; Sanz MÁ; Sanz G; Sanz J
    Transplant Cell Ther; 2021 Mar; 27(3):261.e1-261.e7. PubMed ID: 33781531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical value of plasma and peripheral blood mononuclear cells Epstein-Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation.
    Zhou X; Lu X; He J; Xu Z; Li Q; Ye P; Zhong Z; Shi W; Yan H; You Y; Hu Y; Wang H
    Front Cell Infect Microbiol; 2022; 12():980113. PubMed ID: 36189344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm.
    Piccin A; Morello E; Svaldi M; Haferlach T; Facchetti F; Negri G; Vecchiato C; Fisogni S; Pusceddu I; Cortelazzo S
    Hematol Oncol; 2012 Dec; 30(4):210-3. PubMed ID: 22915052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.